Adaptive Biotechnologies Corp (ADPT) stock
Close on Nov 17, 2026Market cap $4.55BP/E –Yield –
Earnings
Adaptive Biotechnologies's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Adaptive Biotechnologies's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 4, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | $83.90M | -10.7% | $0.02 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 29, 2026after the close | $71.60M | +21.6% | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026after the close | $70.90M | +35.3% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 5, 2026after the close | $71.70M | +50.9% | -$0.09 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025after the close | $94.00M | +102.6% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025after the close | $58.90M | +36.3% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 1, 2025after the close | $52.40M | +25.1% | -$0.20 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 11, 2025after the close | $47.50M | +3.7% | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | $46.40M | +22.4% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024after the close | $43.20M | -11.7% | -$0.31 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024after the close | $41.90M | +11.4% | -$0.33 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 14, 2024after the close | $45.80M | -17.0% | -$0.48 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023after the close | $37.90M | -20.7% | -$0.35 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 2, 2023after the close | $48.90M | +11.9% | -$0.33 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023after the close | $37.60M | -2.6% | -$0.40 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 14, 2023after the close | $55.20M | +45.6% | -$0.28 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022after the close | $47.80M | +21.0% | -$0.32 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022after the close | $43.70M | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022after the close | $38.60M | – | -$0.44 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 15, 2022after the close | $37.90M | – | -$0.43 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021after the close | $39.50M | – | -$0.40 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 24, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 10, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Adaptive Biotechnologies's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| MRD revenue | FY2026 | $268.00M – $278.00M | $260.00M – $270.00M | Raised | Jul 29, 2026 |
| revenue for the MRD business | FY2026 | $276.00M – $286.00M | $255.00M – $265.00M | Raised | Nov 4, 2026 |
| MRD revenue annual growth | FY2026 | +26% – +31% | – | New | Jul 29, 2026 |
| total company operating expenses, including cost of revenue | FY2026 | $350.00M | $350.00M – $360.00M | Lowered | Nov 4, 2026 |
| total company operating expenses, including cost of revenue | FY2026 | $350.00M – $355.00M | $350.00M – $360.00M | Lowered | Jul 29, 2026 |
Guidance vs results
The last range Adaptive Biotechnologies gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $202.00M – $207.00M | $277.00MΣ4Q | Above range |
Guidance history
Every forecast Adaptive Biotechnologies put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | total company operating expenses, including cost of revenue | FY2026 | $350.00M | Lowered |
| Nov 4, 2026 | revenue for the MRD business | FY2026 | $276.00M – $286.00M | Raised |
| Jul 29, 2026 | MRD revenue annual growth | FY2026 | +26% – +31% | New |
| Jul 29, 2026 | total company operating expenses, including cost of revenue | FY2026 | $350.00M – $355.00M | Lowered |
| Jul 29, 2026 | MRD revenue | FY2026 | $268.00M – $278.00M | Raised |
| May 5, 2026 | total company operating expenses, including cost of revenue | FY2026 | $350.00M – $360.00M | New |
| May 5, 2026 | revenue for the MRD business | FY2026 | $260.00M – $270.00M | New |
| Feb 5, 2026 | total company operating expenses, including cost of revenue | FY2026 | $350.00M – $360.00M | New |
| Feb 5, 2026 | revenue for the MRD business | FY2026 | $255.00M – $265.00M | New |
| Nov 5, 2025 | operating expenses, including cost of revenue | FY2025 | $335.00M – $340.00M | New |
| Nov 5, 2025 | total company cash burn | FY2025 | $45.00M – $50.00M | Lowered |
| Nov 5, 2025 | full year revenue for the MRD business | FY2025 | $202.00M – $207.00M | New |
| Aug 5, 2025 | total company operating expenses, including cost of revenue | FY2025 | $335.00M – $345.00M | Raised |
| Aug 5, 2025 | total company cash burn | FY2025 | $45.00M – $55.00M | Lowered |
| Aug 5, 2025 | revenue for the MRD business | FY2025 | $190.00M – $200.00M | Raised |
| May 1, 2025 | total company operating expenses, including cost of revenue | FY2025 | $335.00M – $345.00M | Raised |
| May 1, 2025 | total company cash burn | FY2025 | $50.00M – $60.00M | Lowered |
| May 1, 2025 | revenue for the MRD business | FY2025 | $180.00M – $190.00M | Raised |
| Feb 11, 2025 | total company operating expenses, including cost of revenue | FY2025 | $340.00M – $350.00M | New |
| Feb 11, 2025 | total company cash burn | FY2025 | $60.00M – $70.00M | New |
| Feb 11, 2025 | revenue for the MRD business | FY2025 | $175.00M – $185.00M | New |
| Nov 7, 2024 | operating expenses, including cost of revenue and excluding one-time costs from asset impairments and other restructuring charges | FY2024 | $335.00M – $340.00M | New |
| Nov 7, 2024 | revenue for the MRD business | FY2024 | $143.00M – $145.00M | Raised |
| Aug 1, 2024 | total company operating expenses | FY2024 | $340.00M – $350.00M | New |
| Aug 1, 2024 | revenue for the MRD business | FY2024 | $140.00M – $145.00M | New |
| May 7, 2024 | total company operating expenses, including cost of revenue | FY2024 | $350.00M – $360.00M | Lowered |
| May 7, 2024 | revenue for the MRD business | FY2024 | $135.00M – $140.00M | Raised |
| Feb 14, 2024 | operating expenses, including cost of revenue | FY2024 | $360.00M – $370.00M | New |
| Feb 14, 2024 | revenue for the MRD business | FY2024 | $130.00M – $140.00M | New |
| Nov 9, 2023 | Total company operating expenses, including cost of revenue | FY2023 | $375.00M | New |
| Nov 9, 2023 | MRD business revenue | FY2023 | $100.00M – $105.00M | Lowered |
| Aug 2, 2023 | revenue | FY2023 | $205.00M – $215.00M | Reaffirmed |
| May 3, 2023 | revenue | FY2023 | $205.00M – $215.00M | Reaffirmed |
| Feb 14, 2023 | revenue | FY2023 | $205.00M – $215.00M | New |
| Nov 3, 2022 | operating expenses | FY2022 | $400.00M | Lowered |
| Nov 3, 2022 | revenue | FY2022 | $185.00M – $190.00M | Lowered |
| Nov 3, 2022 | revenue CAGR | 2022-2027 | +20% – +30% | – |
| Aug 3, 2022 | operating expenses | FY2022 | $410.00M – $415.00M | New |
| Aug 3, 2022 | revenue | FY2022 | $185.00M – $195.00M | Reaffirmed |
| May 4, 2022 | revenue | FY2022 | $185.00M – $195.00M | New |
| Nov 3, 2021 | revenue | FY2021 | $148.00M – $155.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Adaptive Biotechnologies filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?